Zumutor Biologics secured $7.3 million in a Pre-Series B round to advance its immuno-oncology pipeline.
The round saw participation from existing investors Accel and Bharat Innovation Fund, and new investors including Premji Invest and Ashish Kacholia.
The funding serves as a bridge to complete the capital-intensive US FDA Phase 1 clinical trials for lead candidate ZM008 without diluting equity in a full Series B.
Read the full story on StartupFox